Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$64.36M-0.10%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph H. Capper
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 808
- Beta
- 1.42
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 8.07
Financials
Revenue
$64.36M-0.1%Net Income
$-14.84M-546.9%EBITDA
$-16.93M-322.2%Free Cash Flow
$-10.72M-925.4%EPS (diluted)
$-0.10-433.3%Shares Outstanding (diluted)
147.80M+31.5%Operating Expenses
$62.56MCash & Debt
$135.84MReturn of Capital
$12.60MRevenue by Segment (annual)
$142.30MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $418.63M | $48.58M | $0.33 |
| 2024 | $348.88M | $42.42M | $0.29 |
| 2023 | $321.48M | $67.44M | $0.48 |
| 2022 | $267.84M | $-30.20M | $-0.27 |
| 2021 | $242.02M | $-12.30M | $-0.09 |
| 2020 | $248.23M | $-49.28M | $-0.46 |
| 2019 | $299.25M | $-25.58M | $-0.24 |
| 2018 | $359.11M | $-29.98M | $-0.28 |
| 2017 | $321.14M | $64.73M | $0.61 |
| 2016 | $245.01M | $11.97M | $0.00 |
| 2015 | $187.30M | $29.45M | $0.28 |
| 2014 | $118.22M | $6.22M | $0.06 |
| 2013 | $59.18M | $-4.11M | $-0.04 |
| 2012 | $27.05M | $-7.66M | $-0.09 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.48
- Implied price
- $10.14
- Return from $4.70
- 16.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5.04 — today's price is already 6.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 15 | 18 | 21 | 24 | 27 |
|---|---|---|---|---|---|
| -2.0% | -1.1% | 2.6% | 5.8% | 8.7% | 11.3% |
| 3.0% | 4.0% | 7.9% | 11.2% | 14.2% | 17.0% |
| 8.0% | 9.0% | 13.1% | 16.6% | 19.8% | 22.6% |
| 13.0% | 14.1% | 18.3% | 22.0% | 25.3% | 28.3% |
| 18.0% | 19.1% | 23.6% | 27.4% | 30.9% | 34.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
…t Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026 MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern…
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product
View source ↗ - Newsglobenewswire.com·36d ago·Neutral
MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
View source ↗
Earnings
Wed, Nov 4(in 3 weeks)
Consensus estimate $0.00 per share
Typical surprise +28.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-0.05 vs $-0.05miss
- Wed, Apr 29$-0.05 vs $-0.07beat
- Wed, Feb 25$0.14 vs $0.09beat
- Wed, Oct 29$0.15 vs $0.07beat
- Wed, Jul 30$0.10 vs $0.06beat
- Wed, Apr 30$0.06 vs $0.06beat
Estimates and results for MDXG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MDXG officers and directors.
- Bought
- $1.9m
- Sold
- $2.7m
4 trades
13 trades
- Maersk-moller Kimberlysold
- Capper Joseph Hbought
- Maersk-moller Kimberlysold
- Hulse William Frank Ivsold
- Hulse William Frank Ivsold
- Maersk-moller Kimberlysold
- Hulse William Frank Ivsold
- Maersk-moller Kimberlysold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Tom Malinowskihouse · NJ07 · disclosed Jul 9, 2021 (771d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.